The Molecular Efficacy of CRISPR-Cas9 in Treating Alzheimer's Disease

Abstract

Alzheimer's disease (AD), a highly complicated type of neurodegenerative diseases is the brain ailment characterized by the progressive decline in mental function influencing millions of people globally. In spite the developments in molecular biology, it is not fully understood what causes this disease. Mutations in APP, PSEN1, and PSEN2 symptomize AD by building amyloid-beta, a plaque formed in the brains by which neurons communication is hindered triggering cognitive decline, neuronal impairment, and death. Current advances in gene editing have provided new insights into the significant genetic factors take part in the progress of AD. CRISPR-Cas9 is a cutting-edge genome-editing tool used to provide sincere efforts to target and silence infective proteins linked with AD. The main goal of this research is to assess the potential of CRISPR Cas9, as a treatment for Alzheimer’s disease (AD) in addition to reviewing genes for both early and late onset AD.